Mobile: +91 992-500-9739

Tele: +91 79 403-07106

Email: info@newedgeoverseas.com

Allopurinol

Allopurinol supplier & exporter

Product Description

API name Allopurinol
CAS Number 315-30-0
Therapeutic Category Antigout
Route of Administration Tablet, Powder, injection, solution
Regulatory Documents DMF , COS, ASMF, CEP, USDMF, CANADA DMF

Trader & Wholesaler of Allopurinol

Allopurinol is a structural analog of the natural purine base, hypoxanthine. After ingestion, allopurinol is metabolized to its active metabolite, oxypurinol (alloxanthine) in the liver 11, which acts as an inhibitor of xanthine oxidase enzyme Label.

Allopurinol and its active metabolite inhibit xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. Inhibition of this enzyme is responsible for the effects of allopurinol. This drug increases the reutilization of hypoxanthine and xanthine for nucleotide and nucleic acid synthesis by a process that involves the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase). This process results in an increased nucleotide concentration, which causes feedback inhibition of de novo purine synthesis. The end result is decreased urine and serum uric acid concentrations 15, which decreases the incidence of gout symptoms.

Accompanying the reduction of serum uric acid by allopurinol is an increase in the serum and urine concentrations of hypoxanthine and xanthine (due to inhibition of xanthine oxidase). In the absence of allopurinol, regular urinary excretion of oxypurines almost entirely occurs in the form of uric acid. After the ingestion of allopurinol, the contents of excreted urine are hypoxanthine, xanthine, and uric acid. Because each substance has its own individual solubility, the concentration of uric acid in plasma is decreased without exposing the renal tissues to a high load of uric acid, thereby decreasing the risk of crystalluria. By lowering the uric acid concentration in the plasma below its limits of solubility, allopurinol encourages the dissolution of gout tophi. Although the levels of hypoxanthine and xanthine are found to be increased after allopurinol ingestion, the risk of deposition in renal tissues is less than that of uric acid, as they become more soluble and are rapidly excreted by the kidney 15.

Drug Indications:

Allopurinol is indicated in: 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Alimemazine Tartrate/Trimeprazine Tartrate

Alimemazine Tartrate/Trimeprazine Tartrate supplier & exporter

Product Description

API name Alimemazine Tartrate/Trimeprazine Tartrate
CAS Number 4330-99-8
Therapeutic Category Antihistamine
Route of Administration Liquid, tablet
Regulatory Documents USDMF, ASMF, CEP

Trader & Wholesaler of Alimemazine Tartrate/Trimeprazine Tartrate

Mechanism of Action:

Trimeprazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.

Drug Indications:

Used to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions).

Alfuzosin HCl

Alfuzosin HCl supplier & exporter

Product Description

API name Alfuzosin HCl
CAS Number 81403-68-1
Therapeutic Category Antihypertensive
Route of Administration Tablet
Regulatory Documents USDMF, CEP, ASMF

Trader & Wholesaler of Alfuzosin HCl

Mechanism of Action:

Alfuzosin Hydrochloride is the hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance.

Drug Indications:

Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Alfuzosin

Alfuzosin supplier & exporter

Product Description

API name Alfuzosin
CAS Number 81403-80-7
Therapeutic Category Benign Prostatic Hyperplasia (BPH)
Route of Administration Tablet
Regulatory Documents TECH PACK, DMF

Trader & Wholesaler of Alfuzosin

Mechanism of Action:

Alpha(1)-adrenoreceptors are found in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra; their activation may lead to contraction of smooth muscle and urinary symptoms in patients with BPH. Alfuzosin selectively binds to and inhibits alpha(1)-adrenergic receptors in the lower urinary tract. This leads to the relaxation of smooth muscle in both the prostate and bladder neck, resulting in the improvement in urine flow and a reduction of urinary symptoms.

Drug Indications:

Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Alfacalcidol

Alfacalcidol supplier & exporter

Product Description

API name Alfacalcidol
CAS Number 41294-56-8
Therapeutic Category Vitamin D Supplement, Calcium Regulator
Route of Administration Capsule, oral drops, Injection
Regulatory Documents TECH PACK, DMF

Trader & Wholesaler of Alfacalcidol

Mechanism of Action:

In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys’ capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D

 

Drug Indications:

Alfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.

Alendronate Sodium

Alendronate Sodium supplier & exporter

Product Description

API name Alendronate Sodium
CAS Number 121268-17-5
Therapeutic Category Antiosteoporotic
Route of Administration Tablet
Regulatory Documents USDMF, CEP, ASMF, CANADA DMF, TAIWAN DMF, DMF, JDMF, CEP, WC

 

Trader & Wholesaler of Alendronate Sodium

Mechanism of Action:


Alendronic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis.

Drug Indications:

Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget’s disease of bone.

Alectinib HCl

Alectinib HCl supplier & exporter

Product Description

API name Alectinib HCl
CAS Number 1256589-74-8
Therapeutic Category Anticancer, Antineoplastic
Route of Administration Capsule
Regulatory Documents TECH PACK, DMF

Trader & Wholesaler of Alectinib HCl

Mechanism of Action:

Alectinib hydrochloride is an ALK kinase inhibitor, which inhibits ALK phosphorylation and ALK-media- ted activation of the downstream signaling proteins STAT3 and AKT, and decreases tumor cell viability in multiple cell lines harboring ALK fusions,

Drug Indications:

Alectinib HCl as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alectinib

Alectinib supplier & exporter

Product Description

API name Alectinib
CAS Number 1256580-46-7
Therapeutic Category Anticancer, Antineoplastic
Route of Administration Capsule
Regulatory Documents TECH PACK, DMF

Trader & Wholesaler of Alectinib

Mechanism of Action:

Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells.

Drug Indications:

Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib

Alcaftadine

Alcaftadine supplier & exporter

Product Description

API name Alcaftadine
CAS Number 147084-10-4
Therapeutic Category Antihistamine
Route of Administration Drops, Liquid, Solution, ophthalmic
Regulatory Documents USDMF, DMF

Trader & Wholesaler of Alcaftadine

Mechanism of Action:

Alcaftadine is a H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.

Drug Indications:

For the prevention of itching associated with allergic conjunctivitis.

Albendazole

Albendazole supplier & exporter

Product Description

API name Albendazole
CAS Number 54965-21-8
Therapeutic Category Anthelmintic
Route of Administration Tablet, Suspension, coated
Regulatory Documents TECH PACK, DMF, USDMF

Trader & Wholesaler of Albendazol

Mechanism of Action:

Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by diminishing its energy production, ultimately leading to immobilization and death of the parasite. It works by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules.Albendazole also prevents the formation of spindle fibers needed for cell division, which in turn blocks egg production and development; existing eggs are prevented from hatching

Drug Indications:

ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.